CORRECTION -- GeoPharma Announces Fiscal Year 2009 Fourth Quarter and Year End Results


LARGO, Fla., July 1, 2009 (GLOBE NEWSWIRE) -- In a release issued by GeoPharma, Inc. (Nasdaq:GORX) on June 30, 2009 under the same headline, please note that the Pharmaceutical revenues line item wasn't included, causing the numbers for the remaining line items to be incorrect. The corrected table follows:



           CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                                            Fiscal year ended March 31,
 Revenues:                                      2009          2008
                                            --------------------------
 Manufacturing                              $ 20,238,000  $ 24,402,000
 Pharmaceutical                             $  1,721,000  $    232,000
                                            --------------------------
 Total revenues, net                        $ 21,959,000  $ 24,634,165
 Gross Profit                               $  2,904,000  $  3,861,000
 Stock compensation expense                 $  1,461,000  $    957,000
 Depreciation and amortization              $  1,951,000  $  1,721,000
 SG&A                                       $ 13,658,000  $ 10,366,000
                                            --------------------------
 Operating income (loss)                    $(14,165,000) $ (9,183,000)
 Other income / (expense), net              $  2,321,000  $   (373,000)
 Income (loss) from continuing operations
  before minority interest and income tax   $(11,844,000) $ (9,556,000)
 Minority interest                          $    709,000  $    900,000
 Income tax benefit (expense)               $  1,063,000  $  1,228,153
 Income (loss) from continuing operations   $(10,072,000) $ (7,428,000)
 Discontinued operations- Distribution:
 Revenues - Distribution                    $ 41,061,000  $ 30,334,000
 Cost of sales - Distribution               $ 33,514,000  $ 23,328,000
                                            --------------------------
 Gross profit - Distribution                $  7,547,000  $  7,006,000
 SGA - Distribution                         $ 11,800,000  $  8,971,000
 Other income (expense), net - Distribution $    570,000  $  1,087,000
 Asset impairments- Distribution            $ 13,312,000  $         --
 Income tax benefit (expense) - 
  Distribution                              $  1,004,000  $  1,282,000
 Exit income (expense) - Distribution       $         --  $         --
                                            --------------------------
 Income (loss) from discontinued operations
  - Distribution                            $(15,991,000) $    403,000
 Income (loss) from discontinued operations
  - PBM                                     $         --  $      8,400
                                            --------------------------
 Net income (loss)                          $(26,064,000) $ (7,017,000)
 Preferred dividends                        $    576,000  $    408,000
                                            --------------------------
 Net income (loss) available to common
  shareholders                              $(26,640,000) $ (7,425,000)
 Basic and diluted  earnings (loss) per
  common share outstanding                  $      (1.62) $      (0.59)
 Basic weighted average common shares
  outstanding                                 16,446,191    12,541,659
 Basic and diluted earnings (loss) per
  common share outstanding - Distribution   $      (0.97) $       0.03
 Basic and diluted earnings (loss) per
  common share outstanding - PBM            $         --  $         --

            

Contact Data